JPY 1,735 intraday: 3695.T GMO Product Platform (JPX) 21 Feb 2026 AI insight

The 3695.T stock trades at JPY 1,735.00 intraday on the JPX as investors weigh AI-related demand for audience data and platform services. Volume is light at 3,000 shares versus a 50-day average of 7,696, leaving price moves sensitive to news. Fundamentals show an EPS of 64.15 and a PE of 26.66, while the company yields roughly 3.48% in dividend return. This piece links AI strategy and near-term technicals to show how GMO Product Platform, Inc. may reprice if AI services accelerate.

3695.T stock intraday snapshot

Price action is muted today with a day high of JPY 1,735.00 and day low of JPY 1,704.00. The stock opened at JPY 1,704.00 and the previous close was JPY 1,735.00. Trading is thin, with volume 3,000 versus average 7,696, implying low liquidity and wider bid-ask risk for intraday traders.

Fundamentals and valuation

GMO Product Platform, Inc. (3695.T) shows EPS 64.15 and a reported PE 26.66 on the JPX. Market cap stands at JPY 7,529,342,040.00 with 4,403,124 shares outstanding. Price-to-sales sits near 1.10 and price-to-book near 2.92, above Industrials sector averages, indicating a premium for its data and platform assets.

AI strategy fit and growth drivers

GMO Product Platform positions its audience panels and automated data tools to serve AI training and analytics. Management has rebranded toward AI, which could lift revenue per client if demand for labeled datasets increases. Recent financials show three-year revenue per-share growth; weakness in operating cash flow growth is a near-term caution.

Technicals and trading signals

Momentum indicators are bearish: RSI 29.74 (oversold) and MACD histogram negative. Bollinger Bands place the lower band at JPY 1,659.13, so current price sits near support. Relative volume 0.43 confirms muted trading. For active traders, a break above the 50-day average (JPY 2,067.68) would signal short-term trend reversal.

Meyka AI grade, forecast and price targets

Meyka AI rates 3695.T with a score out of 100. Meyka AI rates 3695.T with a score out of 100: score 73.18 | Grade B+ | Suggestion: BUY. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly JPY 1,873.61, quarterly JPY 2,243.14, and yearly JPY 2,577.44. Versus the current JPY 1,735.00, the yearly figure implies 48.56% upside. Forecasts are model-based projections and not guarantees. Suggested price targets: conservative JPY 1,900.00, base JPY 2,243.14, aggressive JPY 2,577.44.

Risks, catalysts and sector context

Key risks include weaker-than-expected AI service adoption, margin pressure, and low trading liquidity. The Industrials sector trade shows average PE 18.54, making GMO’s current PE a premium. Positive catalysts: renewed corporate contracts for data, stronger earnings on 12 May 2026, and AI partnerships that improve recurring revenue. Monitor upcoming earnings announcement on 2026-05-12 for confirmation of AI revenue traction.

Final Thoughts

Short-term the 3695.T stock is trading with low liquidity and oversold technicals, creating a watchlist candidate rather than a high-conviction trade. Fundamentals show solid EPS (64.15) and a modest dividend (JPY 59.52 per share), but operating cash flow weakness and recent revenue declines warrant caution. From an AI-stocks angle, GMO Product Platform’s audience panels and data services could drive re-rating if management converts AI demand into recurring contracts. Meyka AI’s forecast model projects a yearly target of JPY 2,577.44, implying +48.56% from JPY 1,735.00 today; use JPY 1,900.00 as a conservative near-term target and JPY 2,243.14 as a base case. These forecasts are model-based and not guarantees. We note the company’s upcoming earnings on 2026-05-12 as the primary catalyst for any sustained move.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.